Harvard Apparatus adjusted EBITDA rises 11% year over year to $1.7 million; revenue increases 11% to $22.7 million in 2Q26

• Harvard Apparatus Regenerative Technology posted 2Q26 revenue of $22.7 million, up 11% year-over-year.
• GAAP diluted loss per share widened to $(0.64); adjusted diluted loss per share widened to $(0.14).
• Adjusted EBITDA rose 11% to $1.7 million; adjusted gross margin fell 0.5 percentage points to 56.7%.
• Net debt increased to $33.5 million as of June 30, 2026; year-to-date cash flow from operations was $(0.3) million.
• Raised FY26 revenue growth outlook to 3%-5%; 3Q26 guidance calls for revenue of $21.0 million-$22.6 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Harvard Apparatus Regenerative Technology Inc. published the original content used to generate this news brief on August 11, 2026, and is solely responsible for the information contained therein.